Elsevier

Neoplasia

Volume 17, Issue 1, January 2015, Pages 1-15
Neoplasia

Spherical Cancer Models in Tumor Biology1

https://doi.org/10.1016/j.neo.2014.12.004Get rights and content
Under a Creative Commons license
open access

Abstract

Three-dimensional (3D) in vitro models have been used in cancer research as an intermediate model between in vitro cancer cell line cultures and in vivo tumor. Spherical cancer models represent major 3D in vitro models that have been described over the past 4 decades. These models have gained popularity in cancer stem cell research using tumorospheres. Thus, it is crucial to define and clarify the different spherical cancer models thus far described. Here, we focus on in vitro multicellular spheres used in cancer research. All these spherelike structures are characterized by their well-rounded shape, the presence of cancer cells, and their capacity to be maintained as free-floating cultures. We propose a rational classification of the four most commonly used spherical cancer models in cancer research based on culture methods for obtaining them and on subsequent differences in sphere biology: the multicellular tumor spheroid model, first described in the early 70s and obtained by culture of cancer cell lines under nonadherent conditions; tumorospheres, a model of cancer stem cell expansion established in a serum-free medium supplemented with growth factors; tissue-derived tumor spheres and organotypic multicellular spheroids, obtained by tumor tissue mechanical dissociation and cutting. In addition, we describe their applications to and interest in cancer research; in particular, we describe their contribution to chemoresistance, radioresistance, tumorigenicity, and invasion and migration studies. Although these models share a common 3D conformation, each displays its own intrinsic properties. Therefore, the most relevant spherical cancer model must be carefully selected, as a function of the study aim and cancer type.

Cited by (0)

1

Work of the laboratory on spheres is supported by a Genevieve and Jean-Paul Driot Transformative Research Grant, a Philippe, Stéphanie and Laurent Bloch Cancer Research Grant, a Hassan Hachem Translational Medicine Grant, a Sally Paget-Brown Translational Research Grant, the Institut National du Cancer and Cancéropôle Ile de France (COLOMETASTEM grant), and GEFLUC (Grant 5/188).